| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9005766 | Clinical Therapeutics | 2005 | 17 Pages |
Abstract
Anidulafungin may offer a new option to treat serious fungal infections, such as EC, azole-refractory EC, candidemia, and IC. In addition, anidulafungin has been associated with no clinically significant drug-drug interactions and few treatment-related AEs. Anidulafungin may offer a new option in the management of serious and difficult-to-treat invasive fungal infections.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
MD Vazquez,